Lumonus Raises A$25 million Series B to Build the AI “Workflow Layer” for Oncology

Sydney-based HealthTech startup Lumonus has raised A$25 million in Series B funding to accelerate its AI-powered oncology workflow platforms Physician and Dosimetry that aim to make cancer care faster, safer, and more efficient.

Led by Aviron Investment Management with participation from Oncology Ventures, the new funding will support US expansion of Lumonus and deepen its development of AI tools that automate documentation, treatment planning and clinical intelligence. With more than 750 active users and 280,000 cancer treatments supported across hospitals in Australia, the US and Europe, Lumonus is emerging as one of the most promising names in AI-driven oncology software.

The Clinic, Unjammed: How AI is Redefining Oncology Workflows ?

Step into any oncology department and you’ll find clinicians facing not just the burden of cancer itself, but the paperwork that comes with it. From endless data entry to treatment documentation, the administrative load in oncology has quietly become a second disease.

That’s the problem Lumonus is trying to cure.

The Sydney startup’s mission is deceptively simple: remove the friction from cancer care. By building an “AI workflow layer” that integrates across Electronic Medical Records (EMR), Oncology Information Systems (OIS) and Treatment Planning Systems (TPS), Lumonus helps doctors reclaim time for patients, not paperwork.

Instead of building yet another app, Lumonus functions as a smart overlay, automating everything that slows clinicians down from generating notes to optimizing dosimetry plans.

Beyond Apps: Lumonus Builds the AI Workflow Layer for Cancer Care

Healthcare systems don’t need more software; they need smarter systems. Lumonus understands that. Its AI doesn’t replace existing infrastructure — it connects it. The platform syncs with leading EMR, OIS and TPS systems, automating repetitive workflows while maintaining compliance and data integrity.

In a sector where interoperability is often the biggest obstacle, Lumonus’ integration-first architecture has become its biggest advantage. The company calls this approach a “system of intelligence”, a layer that orchestrates, not competes.

It’s this philosophy that differentiates Lumonus from traditional digital health startups. Rather than reinventing hospital systems, it enhances what’s already there, allowing clinicians to achieve better outcomes with less effort.

Inside Lumonus Physician: Automating Consults, Documentation and Clinical Intelligence

The company’s flagship product, Lumonus Physician, acts as a digital assistant for oncologists. It automates the most time-consuming parts of the job, documenting patient interactions, summarizing case data and ensuring compliance with clinical guidelines. Physician is structured around three key functions:

• Consult: Context-aware AI surfaces relevant patient data, generates clinical summaries with source citations and even offers treatment guideline recommendations.
• Document: The system automatically generates SIM orders, planning notes, billing codes and consult notes: all formatted for EMR systems.
• Improve: Embedded analytics visualize metrics like turnaround times, adherence to evidence-based guidelines and care efficiency.

According to Lumonus, its users report an average of 102 minutes saved per patient and 97% guideline adherence, supported by references from The Red Journal (2022) and internal outcome studies. By transforming what used to be hours of admin work into minutes of automated output, Lumonus Physician doesn’t just save time, it restores focus to patient care.

Lumonus Dosimetry: AI-Powered Treatment Planning That Cuts Cost and Error

If Physician assists oncologists, Lumonus Dosimetry empowers medical physicists.

Radiation treatment planning is one of the most complex, precision-driven processes in medicine and one of the most error-prone. Lumonus Dosimetry automates critical steps of this workflow, from plan setup to peer review, using AI and web-based collaboration tools.

Its end-to-end system enables teams to manage, plan, review and improve treatment plans in a single interface. The results are compelling:

• 70% fewer dosimetry errors
• 30% lower costs
• Two days faster planning turnaround

What makes Lumonus Dosimetry distinctive is its human-in-the-loop design, automation doesn’t replace human judgment, it augments it. By managing complexity and surfacing quality issues early, Lumonus gives clinicians confidence in both speed and safety.

Why Oncology Needs Workflow Automation Now More Than Ever ?

The need for this kind of automation has never been greater. According to the World Health Organization, global cancer cases are expected to rise by 77% by 2050. Meanwhile, oncology faces a chronic workforce shortage, with many clinics struggling to meet growing demand.

Physicians spend up to 40% of their time on administrative tasks, time that could be better used on patient interaction or research. Lumonus addresses that gap directly, helping clinics operate with greater throughput and fewer errors. In a healthcare landscape dominated by diagnostics and genomics innovation, focus of Lumonus is on workflow optimization feels refreshingly pragmatic, targeting the invisible inefficiencies that slow care down.

Funding to Scale: Lumonus Raises A$25M Series B to Expand Global Footprint

The A$25 million Series B round marks a major inflection point for Lumonus. Led by Aviron Investment Management, with participation from Oncology Ventures, the funding will accelerate expansion in the United States and Europe and strengthen product development for both Physician and Dosimetry platforms.

The company also plans to scale its engineering team, enhance its interoperability engine and pursue new partnerships with hospital networks. In a statement announcing the funding, Lumonus emphasized its mission to “build the intelligence layer for global oncology care”, one that complements, rather than disrupts, existing clinical systems.

Challenges Ahead for Lumonus: Integration, Regulation & Proof of Clinical Impact

Despite its momentum, Lumonus still faces the same challenges that confront every AI healthcare company. Integration with legacy hospital systems can be slow and resource-intensive. Regulatory scrutiny is rising globally, with the FDA, EMA and TGA all tightening guidelines on AI-based decision support systems.

Then there’s the question of clinical proof. Lumonus claims 97% guideline adherence and 70% error reduction and these are backed by internal modeling and limited published studies. But widespread adoption will depend on independent validation and peer-reviewed evidence.

Still, the pragmatic strategy of Lumonus is to focus on workflow automation rather than diagnostic judgment. This may allow it to navigate regulatory frameworks faster than AI models that make clinical decisions outright.

The Future of Cancer Care Automation: From Efficiency to Intelligent Collaboration

As Lumonus scales, its vision extends beyond efficiency toward intelligent collaboration, a future where every treatment plan, every patient note and every workflow feeds data back into a learning system that improves over time. The company envisions oncology as a continuously optimizing ecosystem, not just powered by AI, but in partnership with clinicians.

From saving minutes in documentation to saving lives through better accuracy, Lumonus represents a new philosophy in health tech: AI not as a replacement for human expertise, but as an amplifier of it.

If successful, the Sydney startup could do more than automate cancer care, it could redefine how healthcare systems everywhere think about time, trust and teamwork.